What is Molecular Assemblies?
Molecular Assemblies is at the forefront of developing a novel enzymatic DNA synthesis technology. This patented method mimics nature's own process for creating DNA, aiming to produce long, high-quality, and sequence-specific DNA reliably, affordably, and sustainably. The company's innovative approach is poised to revolutionize DNA-based products across multiple sectors, including industrial synthetic biology, precision medicine, DNA data storage, nanomachines, and bio-based electronics. Headquartered in San Diego, Molecular Assemblies is positioning itself as a key player in the burgeoning field of synthetic biology.
How much funding has Molecular Assemblies raised?
Molecular Assemblies has raised a total of $57.1M across 6 funding rounds:
Private Equity
$4.5M
Angel/Seed
$2.3M
Debt
$150K
Debt
$325K
Series A
$24M
Series B
$25.8M
Private Equity (2016): $4.5M, investors not publicly disclosed
Angel/Seed (2016): $2.3M led by Agilent Technologies, Newport Holdings, LP, Genomics Investment Syndicate, Cavendish Impact Capital Fund, 11.2 Capital, and Alexandria Venture Investments
Debt (2020): $150K supported by PPP
Debt (2021): $325K featuring PPP
Series A (2021): $24M backed by iSelect Fund Management, LYFE Capital, Argonautic Ventures, Alexandria Venture Investments, Codexis, and Agile Technologies
Series B (2022): $25.8M with participation from Codexis, Agilent, Casdin Capital, Argonautic Ventures, iSelect Fund Management, and LYFE Capital
Key Investors in Molecular Assemblies
Agilent Technologies
Agilent Technologies is a global leader in life sciences, diagnostics, and applied markets, providing advanced instruments, software, and services to laboratories worldwide. They support research, clinical diagnostics, and pharmaceutical development.
Newport Holdings, LP
Newport Holding Inc operates within the Lending & Brokerage industry, indicating a potential focus on financial backing and strategic partnerships for portfolio companies.
Cavendish Impact Capital Fund
Cavendish Global is a community focused on connecting health and life sciences innovators with impact investors, aiming to bridge the 'Valley of Death' in commercialization and accelerate groundbreaking ideas.
What's next for Molecular Assemblies?
The recent strategic investment in Molecular Assemblies signals a pivotal growth phase for the company. This capital infusion is expected to accelerate the scaling of its enzymatic DNA synthesis technology and expand its market reach. With a clear trajectory from early-stage development to scaling operations, the company is well-positioned to capitalize on the increasing demand for advanced DNA solutions. Future developments will likely focus on commercializing its technology for industrial and medical applications, further solidifying its role in driving innovation in life sciences and beyond.
See full Molecular Assemblies company page
